Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

EWS/ETS-driven Ewing Sarcoma requires BET bromodomain proteins.

Gollavilli PN, Pawar A, Wilder-Romans K, Ramakrishnan N, Engelke CG, Dommeti VL, Krishnamurthy PM, Nallasivam A, Apel IJ, Xu T, Qin Z, Feng FY, Asangani IA.

Cancer Res. 2018 Jun 13. pii: canres.0484.2018. doi: 10.1158/0008-5472.CAN-18-0484. [Epub ahead of print]

PMID:
29898995
2.

FOXM1 is a critical driver of lung fibroblast activation and fibrogenesis.

Penke LR, Speth JM, Dommeti VL, White ES, Bergin IL, Peters-Golden M.

J Clin Invest. 2018 Jun 1;128(6):2389-2405. doi: 10.1172/JCI87631. Epub 2018 May 7.

3.

BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer.

Asangani IA, Wilder-Romans K, Dommeti VL, Krishnamurthy PM, Apel IJ, Escara-Wilke J, Plymate SR, Navone NM, Wang S, Feng FY, Chinnaiyan AM.

Mol Cancer Res. 2016 Apr;14(4):324-31. doi: 10.1158/1541-7786.MCR-15-0472. Epub 2016 Jan 20.

4.

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.

Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, Escara-Wilke J, Wilder-Romans K, Dhanireddy S, Engelke C, Iyer MK, Jing X, Wu YM, Cao X, Qin ZS, Wang S, Feng FY, Chinnaiyan AM.

Nature. 2014 Jun 12;510(7504):278-82. doi: 10.1038/nature13229. Epub 2014 Apr 23.

Supplemental Content

Loading ...
Support Center